Merck, SML1307-5MG, K02288

General description
K02288 is a 2-aminopyridine compound.
Biochem/physiol Actions
K02288 is a selective and potent inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases with IC₅₀s in the range 1–2 nM against ALK1 and ALK2. K02288 has IC₅₀ values of 1.1, 1.8, 6.4 nM for ALK2, ALK1 and ALK6 respectively and IC₅₀s of 34.4, 302, 321 and 220 nM for other ALKs (3, 4, 5) and ActRIIA. K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos.
K02288 is a selective and potent inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases.
K02288 is functionally similar to dorsomorphin, which is known to be the first small-molecule for BMP signaling inhibition.
BMP signalling is associated with many important physiological processes. It acts a central regulator of developmental processes such as organogenesis, gastrulation, mesoderm induction and endochondral bone formation. BMP signals are also related to diseases including pulmonary hypertension, juvenile polyposis syndrome, fibrodysplasia ossificans progressiva and hereditary hemorrhagic telangiectasia syndrome. BMP signaling inhibition might serve as a tool to study its role in other biological processes.